US Patent Issued to Astellas Pharma, National Center for Global Health and Medicine, Hiroshima University on Feb. 24 for "Cell penetrating peptide" (Japanese Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,522, issued on Feb. 24, was assigned to Astellas Pharma Inc. (Tokyo), National Center for Global Health and Medicine (Tokyo) and Hiroshima University (Hiroshima, Japan).

"Cell penetrating peptide" was invented by Hideki Endo (Tokyo), Yukihito Ishizaka (Tokyo), Akira Ishiguro (Tokyo), Tomoki Takashina (Tokyo), Takashi Yamamoto (Hiroshima, Japan) and Tetsushi Sakuma (Hiroshima, Japan).

According to the abstract* released by the U.S. Patent & Trademark Office: "An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO...